Rockefeller Capital Management L.P. Has $45.45 Million Position in Medtronic plc (NYSE:MDT)

Rockefeller Capital Management L.P. decreased its holdings in shares of Medtronic plc (NYSE:MDT - Free Report) by 1.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 504,845 shares of the medical technology company's stock after selling 6,262 shares during the quarter. Rockefeller Capital Management L.P.'s holdings in Medtronic were worth $45,451,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in MDT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Medtronic by 436.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,343,385 shares of the medical technology company's stock worth $661,125,000 after buying an additional 5,975,110 shares in the last quarter. Bank of Montreal Can lifted its holdings in Medtronic by 65.0% in the 3rd quarter. Bank of Montreal Can now owns 4,546,819 shares of the medical technology company's stock worth $406,122,000 after buying an additional 1,790,483 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Medtronic by 1,195.9% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,837,600 shares of the medical technology company's stock worth $144,637,000 after buying an additional 1,695,800 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in Medtronic by 8,908.6% in the 3rd quarter. International Assets Investment Management LLC now owns 1,298,415 shares of the medical technology company's stock worth $116,896,000 after buying an additional 1,284,002 shares in the last quarter. Finally, Troy Asset Management Ltd acquired a new position in Medtronic in the 2nd quarter worth $85,440,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Medtronic Stock Performance

Shares of NYSE:MDT traded up $0.27 during trading on Friday, reaching $86.54. 3,543,192 shares of the company's stock traded hands, compared to its average volume of 6,272,690. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.84 and a quick ratio of 1.39. The stock has a market capitalization of $110.98 billion, a P/E ratio of 26.46, a price-to-earnings-growth ratio of 2.44 and a beta of 0.84. The company has a 50 day moving average of $88.69 and a 200-day moving average of $84.99. Medtronic plc has a 12 month low of $75.96 and a 12 month high of $92.68.

Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The firm had revenue of $8.40 billion during the quarter, compared to analysts' expectations of $8.27 billion. During the same period in the prior year, the company earned $1.25 earnings per share. The company's quarterly revenue was up 5.2% on a year-over-year basis. On average, equities analysts expect that Medtronic plc will post 5.46 EPS for the current year.

Analysts Set New Price Targets

MDT has been the topic of a number of recent analyst reports. Robert W. Baird cut their price objective on shares of Medtronic from $96.00 to $93.00 and set a "neutral" rating on the stock in a report on Wednesday, November 20th. UBS Group raised shares of Medtronic from a "sell" rating to a "neutral" rating and boosted their target price for the stock from $76.00 to $90.00 in a research report on Thursday, August 15th. Needham & Company LLC reissued a "hold" rating on shares of Medtronic in a research report on Monday, November 18th. JPMorgan Chase & Co. dropped their target price on shares of Medtronic from $99.00 to $96.00 and set a "neutral" rating for the company in a research report on Friday, November 15th. Finally, Piper Sandler boosted their target price on shares of Medtronic from $85.00 to $90.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $95.27.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.